Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL2076691 | 0.88 | MAPT (0.53) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL1996992 | 0.82 | F2 (0.50) | MAPTALDH1A1GAARAB9ANPC1 | |
| SCHEMBL3238888 | 0.81 | ADRA2A (0.50) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL10310275 | 0.80 | MAPT (0.56) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL6926083 | 0.79 | MAPT (1.00) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL1379670 | 0.79 | MAPT (0.66) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL9725156 | 0.79 | MAPT (0.78) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL6703272 | 0.78 | NOX1 (0.54) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL10310226 | 0.77 | MEN1 (0.52) | MAPTALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL15986778 | 0.77 | ADRA2A (0.43) | MAPTALDH1A1GAASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114096550-B | Modified nucleosides and methods of synthesis thereof | 斯微(上海)生物科技股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-114096550-A | Modified nucleosides and methods of synthesis thereof | 斯微(上海)生物科技股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2010-06-24 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| CN-1989138-A | 2-Substituted-4-heteroaryl-pyrimidines useful in the treatment of proliferative diseases | CYCLACEL LTD (GB) | 2007-06-27 | — | — | CN | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| EP-1581231-A1 | ANTI-VIRAL COMPOUNDS | Cyclacel Limited (GB) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | MAPT 2289/4885ALDH1A1 3103/4885GAA 2384/4885 |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | MAPT 2054/4885ALDH1A1 2743/4885GAA 1172/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | MAPT 2289/4885ALDH1A1 3103/4885GAA 2384/4885 |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | ADRB2, ADRA2A, ADRA2C | MAPT 3349/4885ALDH1A1 642/4885GAA 2682/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | MAPT 2133/4885ALDH1A1 2550/4885GAA 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.